Compare MEG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | ARVN |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.3M | 806.0M |
| IPO Year | 2020 | 2018 |
| Metric | MEG | ARVN |
|---|---|---|
| Price | $26.72 | $12.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $33.50 | $17.80 |
| AVG Volume (30 Days) | 331.8K | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $826,323,000.00 | $312,300,000.00 |
| Revenue This Year | $19.70 | $11.06 |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.77 | ★ 93.86 |
| 52 Week Low | $10.51 | $5.90 |
| 52 Week High | $32.00 | $22.48 |
| Indicator | MEG | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 58.46 |
| Support Level | $25.75 | $12.47 |
| Resistance Level | $27.63 | $13.56 |
| Average True Range (ATR) | 0.78 | 0.54 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 69.52 | 54.68 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.